Clinical trial
Imatinib Mesylate in Treating Patients With Myelofibrosis
NCT00245128 · OHSU Knight Cancer Institute, Other · Terminated
Key facts
| NCT number | NCT00245128 |
|---|---|
| Title | Imatinib Mesylate in Treating Patients With Myelofibrosis |
| Official title | A Phase II Pilot Study to Determine the Safety and Preliminary Efficacy of Imatinib Mesylate (Gleevec) in Patients With Myelofibrosis With Myeloid Metaplasia |
| Lead sponsor | OHSU Knight Cancer Institute, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Chronic Myeloproliferative Disorders |
| Intervention type | Drug |
| Interventions | imatinib mesylate |
| Enrollment | 10 |
| Start date | Aug 1, 2005 |
| Primary completion | Mar 1, 2007 |
| Completion | Oct 1, 2011 |
| First posted | Oct 27, 2005 |
| Last update posted | Jan 13, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: